Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as anito-cel
anito-cel (anitocabtagene autoleucel) · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| Anito-cel (Dose Escalation) | EXPERIMENTAL | Participant will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of anito-cel. Anito-cel will be given at one of several possible doses in dose escalation until the optimal dose is identified. |
| Anito-cel (Dose Expansion) | EXPERIMENTAL | Participant will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of anito-cel. Anito-cel will be given at the optimal dose identified in dose escalation. |
| Name | Type | Description |
|---|---|---|
| anito-cel | BIOLOGICAL | Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain |
| Cyclophosphamide | DRUG | Administered intravenously |
| Fludarabine | DRUG | Administered intravenously |
Key Inclusion Criteria: * Individuals must be 18 years of age or older * Must have Myasthenia Gravis Foundation of America (MGFA) clinical classification Grades 2-4A at time of screening * Participant must have clinically active disease and requiring ongoing therapy for Generalized Myasthenia Gravi...
Anitocabtagene autoleucel, also known as anito-cel, is an investigational CAR-T cell therapy developed by Arcellx, Inc. It is being studied in non-oncology plasma cell-related diseases, including muscular and neuromuscular conditions such as myasthenia gravis and muscle weakness. It is in Phase 1 clinical development.
Anito-cel is being studied for non-oncology plasma cell-related diseases. The Phase 1 trial enrolls adults with conditions that include muscular diseases, neuromuscular manifestations, autoimmune diseases, autoimmune diseases of the nervous system, myasthenia gravis, and muscle weakness. It is investigational and has not been established as a treatment.
Anito-cel is being developed by Arcellx, Inc., which trades under the ticker ACLX. The company is sponsoring the Phase 1 study of anitocabtagene autoleucel in non-oncology plasma cell-related diseases.
Anito-cel is in Phase 1 clinical development. Anitocabtagene autoleucel is investigational and is being evaluated in a single recruiting Phase 1 study in non-oncology plasma cell-related diseases. It has not completed a pivotal trial.
Anito-cel is being studied in trial NCT06626919, a Phase 1 study of anitocabtagene autoleucel in participants with non-oncology plasma cell-related diseases. The trial is recruiting in the United States, is controlled, is not randomized or double-blind, and plans to enroll about 30 participants aged 18 years and older.
Yes, anito-cel is the short name for anitocabtagene autoleucel. Both names refer to the same investigational CAR-T cell therapy developed by Arcellx, Inc. (ACLX) and being studied in a Phase 1 trial in non-oncology plasma cell-related diseases.